新型降糖药微血管获益:肾脏结局的系统综述与网络荟萃分析
该研究通过MEDLINE系统检索纳入7项观察肾脏安全性终点的随机试验,采用贝叶斯框架固定效应模型网络荟萃分析,比较SGLT-2i、GLP-1ra与DPP-4i对复合肾脏结局风险的影响。与安慰剂相比,达格列净风险降低最显著(HR 0.53;95%可信区间0.43-0.66),其次为恩格列净、卡格列净、司美格鲁肽和利拉鲁肽,利格列汀未见显著降低。
要点
- 达格列净较安慰剂显著降低复合肾脏结局风险(HR 0.53;95%可信区间0.43-0.66)。
- 恩格列净、卡格列净、司美格鲁肽和利拉鲁肽也显示风险降低。
- 利格列汀未显示对复合肾脏结局风险的显著降低。
核心结论
- 与安慰剂相比,达格列净与复合肾脏结局风险降低幅度最大(HR 0.53;95%可信区间0.43-0.66),其次为恩格列净、卡格列净、司美格鲁肽和利拉鲁肽,利格列汀未显示显著降低。
研究设计与样本
- 在MEDLINE进行系统文献检索,筛选观察新型降糖药肾脏安全性终点的随机试验,由两名独立评价者选出7项符合条件的研究进行分析。
- 纳入研究发表于2013年1月至2020年3月,对象为成人,全文为英文,并观察复合肾脏结局。
- 采用贝叶斯框架、固定效应模型及无信息先验进行网络荟萃分析。
主要发现
- 纳入研究在基线平均年龄、糖化血红蛋白A1c(HbA1c)和2型糖尿病平均病程方面总体可比。
- 达格列净较安慰剂降低复合肾脏结局风险(HR 0.53;95%可信区间0.43-0.66),降幅最大。
- 恩格列净、卡格列净、司美格鲁肽和利拉鲁肽也显示风险降低。
- 利格列汀未显示对复合肾脏结局风险的显著降低。
临床怎么用
- 对于2型糖尿病合并肾脏风险的患者,可优先考虑具有肾脏结局获益证据的SGLT-2i(如达格列净),并结合GLP-1ra选择。
局限性
- 大型随机临床试验中肾脏安全性终点数据稀缺。
- 尽管异质性统计量较低,各试验在研究设计和基线人口学特征上仍存在轻微差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetic kidney disease affects nearly one-third of US adults with prevalent type 2 diabetes mellitus (T2DM). The use of new antidiabetic medications in the prevention and treatment of diabetic kidney disease is a growing area of research interest. OBJECTIVE: We sought to characterize the risk of developing a composite kidney outcome among patients receiving a new antidiabetic medication of the SGLT-2i, GLP-1ra, and DPP-4i drug classes. METHODS: We conducted a systematic literature search in MEDLINE to identify randomized trials observing kidney safety endpoints associated with the use of new antidiabetic medications. Two independent reviewers selected the 7 eligible studies for analysis. Included studies were published between January 2013 and March 2020, conducted with adult participantss, published full-text in English, and observed composite kidney outcomes. A network meta-analysis was conducted within a Bayesian framework using a fixed-effects model with uninformative priors. RESULTS: A qualitative assessment of transitivity was conducted to ensure similar distribution of potential modifiers across studies. Included studies were generally comparable in mean age, glycated hemoglobin A1c (HbA1c), and mean duration of T2DM at baseline. MAIN CONCLUSIONS: Compared with placebo, dapagliflozin was associated with the greatest reduction in risk of developing the composite kidney outcome (hazard ratio 0.53; 95% credible interval, 0.43-0.66) followed by empagliflozin, canagliflozin, semaglutide, and liraglutide. Linagliptin did not show a significant reduction in risk of the outcome. LIMITATIONS: This analysis was limited by the scarcity of data for kidney safety endpoints in large, randomized clinical trials. Although the heterogeneity statistic was low, there are slight differences in study design and baseline demographic characteristics across trials.
引用
- Cha AS, Chen Y, Fazioli K, et al. Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes. J Clin Endocrinol Metab. 2021. PMID: 33248440. doi:10.1210/clinem/dgaa894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。